Panagis Galiatsatos, M.D., Baltimore, is a pulmonologist who specialized in COPD, asthma, tobacco dependence and health equity.[1]Galiatsatos is the director of the Tobacco Treatment Clinic at Johns Hopkins Medicine.[2]As Johns Hopkins Medicine lung disease expert Galiatsatos , MD, MHS notes , COVID-19 can cause various lung-related complications and long-lasting damage.[3]First of all, according to Galiatsatos, M.D., M.H.S., a lung disease expert at Johns Hopkins Bayview Medical Center, this virus can lead to pneumonia and, in the most severe cases, acute respiratory distress syndrome, or ARDS.[4]Galiatsatos recommends that people find alternative coping mechanisms to treat anxiety during the pandemic.[5]Based on their findings, Galiatsatos and his colleagues recommend that ADI be used to identify vulnerable populations at greatest risk for readmissions following hospitalization for sepsis.[6]
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
6
513
238
South Korean-based Enzychem Lifesciences just announced that the US Food and Drug Administration has accepted its Investigational New Drug Application to evaluate its lead therapeutic candidate EC-18, in a Phase 2 clinical trial in patients with Acute Respiratory Disease Syndrome due to COVID-19 pneumonia. However, if someone develops a cough, fever, and difficulty breathing, this can lead to more severe problems, including a severe or critical condition called acute respiratory distress syndrome.[3]
08/15/2020
If you were to exclude smokers, only about 16.1 percent of young adults in her study were faced with risk of severe Covid-19. What do we know about smoking and Covid-19? – Adams chose to include vaping in her estimation of risk for young adults because of indications that it may elevate the risk of severe illness.[2]
07/17/2020
Diagnostic error for 15 diseases from the 'Big Three' categories ranged from 2% for heart attacks to 62% for a spinal abscess. Now, researchers at Johns Hopkins Medicine have reported that a class of drugs commonly used to treat erectile dysfunction also may provide sustained relief of symptoms among patients with CP/CPPS. In their study, Herati and his colleagues gave tadalafil to 25 men between the ages of 18 and 66 who had been diagnosed with CP/CPPS and then evaluated them after three months for changes in pain, urinary symptoms and quality of life.[6]
05/15/2020